Publications by authors named "G R Ehresmann"

Article Synopsis
  • The COVID-19 pandemic has multiple phases, with current treatment strategies largely focusing on late-stage disease in hospitals, while the viral phase in outpatients remains a key issue.* -
  • A review of 111 publications identified only 21 focusing on outpatient care, highlighting an imbalance in research and available treatments for patients not requiring hospitalization.* -
  • The authors advocate for public health authorities to approve low-risk treatments for outpatients alongside vaccination efforts, especially in light of emerging SARS-CoV-2 variants and limited monoclonal antibody supply.*
View Article and Find Full Text PDF
Article Synopsis
  • COVID-19, caused by the SARS-CoV-2 virus, is a significant health issue that first emerged in December 2019 in Wuhan, China, leading to various treatments being explored over time.
  • The text discusses the importance of understanding the different stages and phases of COVID-19 to effectively time the use of therapeutics and improve patient outcomes.
  • The authors propose a framework that outlines key periods and phases of the disease, which can help guide research and treatment decisions for COVID-19 therapies.
View Article and Find Full Text PDF

Purpose: The objective of this study is to compare how likely positive tuberculin skin test (TST) and T-SPOT(®).TB (TSPOT) results predict risk factors for tuberculosis in a predominantly immigrant patient population at risk of latent TB infection (LTBI) and with rheumatologic conditions requiring immunomodulatory therapy (IMT).

Methods: Prospective study conducted at a referral rheumatology clinic.

View Article and Find Full Text PDF

Acquired factor VIII deficiency due to antibody inhibition can result in life-threatening hemorrhage. Rarely such antibody inhibition of factor VIII can be associated with other autoimmune disorders including rheumatoid arthritis. We present the first case of a patient with active rheumatoid arthritis and refractory bleeding diatheses due to a factor VIII inhibitor who was successfully treated with rituximab.

View Article and Find Full Text PDF